Magnesium Oxide and Letrozole Versus Letrozole Alone on Ovarian Response in Insulin Resistant PCOS
Key facts
- Who runs it
- Bangladesh Medical University
- Where
- Bangladesh1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 1 Jun 2025
- Ended
- 28 May 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Experimental drug: Magnesium oxide (365 mg)
- Letrozole 2.5mg
- Record updated
- 14 August 2026
Who can take part
- Age
- 18 years to 35 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- All PCOS patients who fulfill the Rotterdam diagnostic criteria
- Primary or secondary subfertility
- Women of age: 18-35yr
- Insulin resistance (HOMA-IR>2) (Hydrie et al.,2012)
Who cannot take part
- Male factor; Uterine, tubal and endometrial factor; Pelvic inflammatory disease; Patient with other endocrine disease like hypothyroidism, hyperthyroidism, congenital adrenal hyperplasia, Diabetes mellitus and hyperprolactinemia; BMI less than 18.5 or more than 30; Known allergy to magnesium oxide; Any medication in the last 3 months which would affect insulin resistance (metformin, myoinositol); Conditions with a high risk for hypomagnesemia such as using diuretics, alcoholism, persistent diarrhoea
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Does pretreatment with magnesium oxide followed by letrozole increase ovulation rate? What medical problems do participants have when taking drug magnesium oxide and letrozole? Researchers will compare magnesium oxide and letrozole to letrozole alone to see pretreatment with magnesium oxide followed by letrozole works better as ovulation induction.
Read full original descriptionShow less
Experimental group will receive magnesium oxide and letrozole alone. Comparator group will receive letrozole alone.
The 2 groups in the trial
- Experimental arm: Magnesium oxide and letrozoleTreatment being tested
Participants will receive tab magnesium oxide 365mg twice daily for 3months followed by tab letrozole 2.5mg 3 tablets daily at night from 2nd to 6th day of menstruation.
Treatment: Experimental drug: Magnesium oxide (365 mg)
- Comparator group: LetrozoleExisting treatment, for comparison
Participants will receive 2.5mg of letrozole, 3 tablets at night from 2nd to 6th day of menstruation.
Treatment: Letrozole 2.5mg
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Pretreatment With Magnesium Oxide Followed by Letrozole on Ovarian Response in Subfertile Women With Insulin Resistant Polycystic Ovarian Syndrome in Comparison to Letrozole Alone
- Record updated
- 14 August 2026